Price range: $116.00 through $195.00
Cagrilintide is a novel, investigational, long-acting synthetic analog of the natural hormone Amylin. It is an amylin receptor agonist (and calcitonin receptor agonist) developed by Novo Nordisk for once-weekly subcutaneous administration. Its primary action is to suppress appetite, promote satiety, and delay gastric emptying. While effective as a monotherapy for weight loss, it is most promising in combination with the $text{GLP}-1$ agonist semaglutide (CagriSema), where it targets a complementary pathway to achieve significantly greater reductions in body weight and better metabolic control.
Cagrilintide is designed to mimic the action of amylin, a hormone co-secreted with insulin from the pancreatic $beta$-cells in response to a meal. Amylin plays a key role in postprandial (post-meal) glucose regulation and energy balance.
| Optional Specification | 5mg*10vials/10mg*10vials, 10mg*10vials/10mg*10vials |
|---|
Reviews
There are no reviews yet.